Condition: Neoplasms · Sponsor: GlaxoSmithKline
The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of testing. The study will also check whether the drug can shrink tumours or slow cancer growth, monitor how the body absorbs and breaks down the drug, and look for any immune reactions that the body might develop against the treatment.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Philadelphia, Pennsylvania, United States | Recruiting |
| GSK Investigational Site | San Antonio, Texas, United States | Recruiting |
| GSK Investigational Site | Toronto, Ontario, Canada | Recruiting |
| GSK Investigational Site | Montreal, Quebec, Canada | Recruiting |
| GSK Investigational Site | Montreal, Quebec, Canada | Recruiting |
| GSK Investigational Site | Helsinki, Finland | Recruiting |
| GSK Investigational Site | Saitama, Japan | Recruiting |
| GSK Investigational Site | Shizuoka, Japan | Recruiting |
| GSK Investigational Site | Tokyo, Japan | Recruiting |
| GSK Investigational Site | Tokyo, Japan | Recruiting |
| GSK Investigational Site | Barcelona, Spain | Recruiting |
| GSK Investigational Site | Madrid, Spain | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07438782